...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Remission Rates with Milnacipran 100 Mg/Day and 150 Mg/Day in the Long-Term Treatment of Major Depression
【24h】

Remission Rates with Milnacipran 100 Mg/Day and 150 Mg/Day in the Long-Term Treatment of Major Depression

机译：Milnacipran在长期抑郁症的长期治疗中的缓解率分别为100 Mg /天和150 Mg /天

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of this study was to determine remission rates during treatment with two different dosages of milnacipran, and the effect of milnacipran therapy for at least 1 year on the maintenance of remission and tolerability, in outpatients with major depression.Methods:The study included 41 outpatients with major depression who initially received milnacipran 50 mg/day for 1-2 weeks, followed by a dosage increase to 100 mg/day for 12 weeks. Patients who achieved remission (17-item Hamilton Depression Rating Scale [HDRS] scores ≤7) after 12 weeks of milnacipran 100 mg/day treatment continued at the same dosage and were followed for at least 1 year. For patients who had decreased HDRS scores, but failed to attain remission, the dosage of milnacipran was increased to 150 mg/day, and those who achieved remission were then followed for at least 1 year.Results: Eight out of 41 patients were withdrawn from the study prematurely because of adverse events (eight events in six patients: nausea, thirst, urinary discomfort, rapid pulse, palpitations, staggering sensation or sweating) or as a result of the patient’s decision (two patients). Thirteen (31.7%) of 41 patients achieved remission during treatment with milnacipran 100 mg/day. Of the remaining 20 patients, 17 underwent a dosage increase to 150 mg/day, and 13 achieved remission at a second assessment (cumulative remission rate: 63.4%). No adverse events or recurrence of symptoms were found in any of the patients who achieved remission during the subsequent follow-up period of a minimum of 1 year.Conclusions: The results of this study showed milnacipran 150 mg/day and 100 mg/day to be effective and well tolerated in the long-term treatment of outpatients with major depression, and indicated that a dosage of 150 mg/day is an effective therapeutic option for depression when a dosage of 100 mg/day does not provide a satisfactory response.
机译：背景：本研究旨在确定两种不同剂量的米那普仑治疗期间的缓解率，以及米那普仑治疗至少1年对重度抑郁症患者维持缓解和耐受性的影响。包括41名重度抑郁症的门诊患者，他们最初接受米那普仑50 mg /天，持续1-2周，然后剂量增加至100 mg /天，持续12周。在接受米那普仑100 mg /天治疗12周后获得缓解的患者（17项汉密尔顿抑郁量表[HDRS]得分≤7），以相同剂量继续治疗并随访至少1年。对于HDRS评分降低但未达到缓解的患者，米那普仑的剂量增加至150 mg / day，然后随访达到缓解的患者至少1年。结果：41例患者中有8例退出了研究。由于不良事件（六名患者中的八项事件：恶心，口渴，泌尿不适，快速脉搏，心pal，感觉参差不齐或出汗）或由于患者的决定（两名患者）而过早进行研究。 41例患者中有13例（31.7％）在接受米那普仑100 mg /天治疗期间获得缓解。其余20例患者中，有17例剂量增加至150 mg / day，另有13例在第二次评估后获得缓解（累积缓解率：63.4％）。在随后的至少一年的随访期间，所有缓解的患者均未发现不良事件或症状复发。结论：本研究结果显示米那普仑分别为150 mg /天和100 mg /天。在重度抑郁症的门诊患者的长期治疗中具有良好的耐受性，并指出当100 mg / day的剂量不能提供令人满意的疗效时，150 mg / day的剂量是抑郁症的有效治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号